SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is trending due to significant volume and attention possibly related to its role in AI infrastructure, with community members discussing potential partnerships and upcoming announcements. The stock's increased activity suggests growing interest in its photonics technology and potential for expansion in the AI connectivity market. Some are focused on its patent portfolio while others are looking forward to upcoming news.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IREN is trending as investors discuss its AI cloud services and potential for significant growth in the AI data center market. Community members are highlighting the company's multi-year contracts, revenue projections, and strategic shift from Bitcoin mining to AI infrastructure. Some analysts have given IREN a high price target, contributing to the positive sentiment.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is trending amidst community discussions about a potential new, more affordable Model Y, with debates focusing on its impact on existing Tesla owners and competition within the EV market; some are skeptical, while others anticipate a positive effect on sales volume and market share, especially as the new models offset the end of US tax incentives.

Galecto, Inc. is a clinical-stage biotechnology company, which engages in developing novel small molecule therapeutics that are designed to target the biological processes that lie at the heart of cancer and fibrotic diseases. The firm is also involved in the development of small molecule inhibitors of galectin-3 and LOXL2. The company was founded by Ulf Jörgen Nilsson, Hakon Leffler, Tariq Sethi, and Hans Thalsgård Schambye in 2011 and is headquartered in Boston, MA.

Galecto Inc

Galecto (GLTO) is experiencing significant volatility, driven by a high short interest and low float, leading to a battle between bulls anticipating a short squeeze and bears predicting a crash. The community is actively debating potential price targets and whether it can emulate similar runs seen in other stocks. This action is occurring without any specific news catalyst, contributing to the speculative nature of the trading activity.

NuCana Plc is a clinical stage biopharmaceutical company. It engages in the business of developing a portfolio of new medicines to treat patients with cancer. The company was founded by Hugh Stephen Griffith and Christopher Barry Wood on January 28, 1997 and is headquartered in Edinburgh, the United Kingdom.

NuCana plc - ADR

NuCana plc

NCNA is trending as traders discuss its low float and potential for a significant run, drawing comparisons to other recently volatile stocks. The community is anticipating upcoming data releases and speculating about potential catalysts, including a possible short squeeze. Some investors believe the stock is undervalued, given its cash runway and cancer treatment prospects.

Quantum Computing, Inc. engages in developing novel algorithms and solutions utilizing quantum and quantum-inspired computing to solve difficult problems in various industries. It leverages its expertise in finance, computing, security, mathematics, and physics to develop commercial applications for the financial, security, and government sectors. The company was founded on July 25, 2001 and is headquartered in Hoboken, NJ.

Quantum Computing Inc

QUBT is trending as the quantum computing sector gains momentum, with retail traders actively discussing its potential and comparing it to competitors. Bullish sentiment is fueled by a recent private placement providing substantial funding, while bears express concerns about dilution and the company's underlying financials. Community members are debating whether QUBT can outperform its peers and achieve commercial success in the long term.

Trilogy Metals, Inc. engages in the development and exploration of mineral properties. The firm holds interests in the Upper Kobuk mineral projects that include the Arctic, a copper-zinc-lead-gold-silver and Bornite, a carbonate-hosted copper projects, which is located in the Ambler mining district in Northwest Alaska. The company was founded on April 27, 2011 and is headquartered in Vancouver, Canada.

Trilogy Metals Inc

Trilogy Metals is trending following news of a U.S. government investment, acquiring a 10% stake to support critical mineral exploration in Alaska. Community discussions revolve around a potential short squeeze and whether the stock can reach double digits, though some caution against chasing the rally and point to a possible offering. The surge reflects a broader interest in securing domestic mineral resources.

Churchill Capital Corp. X is a blank check company, which was created for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded by Michael Klein on January 4, 2024 and is headquartered in New York, NY.

Churchill Capital Corp X - Ordinary Shares - Class A

Churchill Capital Corp X 

Churchill Capital Corp X ($CCCX) is trending as chatter increases around its merger with quantum computing company Infleqtion. The community highlights Infleqtion's existing contracts, partnership with NVIDIA, and potential for growth compared to sector peers like $IONQ and $RGTI. Some investors believe $CCCX is currently undervalued and presents a compelling entry point into the quantum computing space.

HIVE Digital Technologies Ltd. engages in building a bridge between the digital currency and blockchain sector and traditional capital markets. It operates data centers for computing and mining cryptocurrencies, including Bitcoin and other coins. The firm owns and operates green energy-powered data center facilities in Canada, Sweden, and Iceland. Its project includes Iceland Cryptocurrency Mining. HIVE Digital Technologies was founded on June 24, 1987 and is headquartered in San Antonio, TX.

HIVE Digital Technologies Ltd.

HIVE Digital Technologies Ltd

HIVE Digital Technologies is trending due to increased Bitcoin production and a recent partnership with Bell Canada on AI infrastructure, sparking excitement around its potential in both sectors. The community is actively discussing the stock's strong assets, Bitcoin mining capabilities, and potential for significant growth. Some traders are drawing comparisons to other high-performing stocks in the sector and anticipating further upward movement.

Archer Aviation, Inc. engages in the development of electric vertical take-off and landing (eVTOL) aircraft. The company was founded by Brett Adcock and Adam Goldstein on October 16, 2018, and is headquartered in San Jose, CA.

Archer Aviation Inc - Ordinary Shares - Class A

Archer Aviation Inc

Archer Aviation is surging amid speculation of a partnership with Tesla, fueled by a teaser video and social media buzz. The community is actively discussing potential price targets and short squeeze opportunities, while also weighing the risks of the rumors being unfounded. Broader interest in the eVTOL sector and Archer's existing partnerships are also contributing to the conversation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Absci Corporation (ABSI) Reports Q2 Loss, Misses Revenue Estimates

ABSCI CORP (ABSI) delivered earnings and revenue surprises of -26.32% and -74.44%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

SAB Biotherapeutics, Inc. (SABS) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

SAB Biotherapeutics (SABS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Absci Corporation (ABSI) Expected to Beat Earnings Estimates: Should You Buy?

ABSCI CORP (ABSI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Amgen (AMGN) Beats Q2 Earnings and Revenue Estimates

Amgen (AMGN) delivered earnings and revenue surprises of +14.45% and +3.52%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Syndax Pharmaceuticals (SNDX) Reports Q2 Loss, Beats Revenue Estimates

Syndax (SNDX) delivered earnings and revenue surprises of +17.00% and +30.74%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Coya Therapeutics, Inc. (COYA) Surges 10.7%: Is This an Indication of Further Gains?

Coya Therapeutics, Inc. (COYA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Absci Corporation (ABSI) Reports Q1 Loss, Misses Revenue Estimates

FDA Approval Race: AI-Powered Innovations Reshape the Healthcare Landscape

FDA Approval Race: AI-Powered Innovations Reshape the Healthcare Landscape FDA Approval Race: AI-Powered Innovations Reshape the Healthcare Landscape PR Newswire VANCOUVER, BC, Feb. 11, 2025 USA News...

Is AMD Stock a Buy, Sell, or Hold on HSBC’s Double Downgrade?

AMD stock fell after an analyst slashed his price target and rating on the stock due to Nvidia competition and weak AI GPU demand.

Absci Corp. shares gained over 4% in the previous session, drawing the most retail interest among biotech stocks on Stocktwits after the company announced a strategic partnership with AMD, which includes a $20 million investment pledge from the chipmaker.&nbsp;This investment, structured as a private investment in public equity (PIPE), reportedly marks AMD’s entry into life sciences, leveraging its AI chips for drug discovery.The collaboration aims to integrate AMD’s high-performance computing capabilities with Absci’s AI-powered de novo antibody design models.&nbsp;The partnership will be showcased at the upcoming 43rd Annual J.P. Morgan Healthcare Conference on Jan. 15, Absci said.Retail engagement on Stocktwits skyrocketed, with message volume surging by 36,900% on Wednesday.&nbsp;Sentiment on the platform for Absi was 'bullish' heading into Friday even as profit-taking set in, as the company revealed another partnership.&nbsp;<figure class="image"><img style="aspect-ratio:1318/324;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/ABSI_sentiment_and_message_volume_Jan_10_premarket_c443462d4e.png" alt="ABSI sentiment and message volume Jan 10 premarket.png" width="1318" height="324"><figcaption>ABSI sentiment and message volume Jan 10 premarket as of 7:50 am ET | source: Stocktwits</figcaption></figure>Absci and Owkin announced they have teamed up to harness their advanced AI platforms to speed up the discovery and design of new medicines. The partnership will focus on creating treatments for cancer and other conditions like immune disorders and inflammation.&nbsp;<stembedurl>https://stocktwits.com/GeraldK75/message/599519367</stembedurl><stembedurl>https://stocktwits.com/J_The_Legend/message/599520163</stembedurl><stembedurl>https://stocktwits.com/GeraldK75/message/599508901</stembedurl>Adding to Wednesday’s optimism, Cathie Wood’s ARK Investment purchased 608,900 Absci shares, through its ARK Genomic Revolution ETF (ARKG), valued at over $1.9 million as of the last close.&nbsp;AI-driven drug discovery is a space being increasingly targeted by major tech players. Last year, Nvidia&nbsp;<a href="https://stocktwits.com/news-articles/markets/5/top-biotech-stocks-with-highest-retail-chatter-in-2024/cJOEinNRjV">invested</a> $50 million in Recursion Pharmaceuticals for similar initiatives.KeyBanc lowered its price target for Absci to $5 from $6&nbsp;on Wednesday but maintained an ‘Overweight’ rating, citing the broader rebound in healthcare technology stocks following Donald Trump’s election.&nbsp;The brokerage said it sees opportunities in companies with strong balance sheets but warned of risks for those with limited profitability.&nbsp;Absci reported $127.1 million in cash and equivalents as of September 30, 2024, down from $145.2 million the previous quarter.Shares of the company remain down over 22% over the past 12 months.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Close up of scientist hand inoculating an agar plates with bacteria in microbiology lab | Image source: Getty Images

Small-Cap Biotech Absci Draws Heavy Attention On $20M AMD Investment Pledge, Retail's Bullish Despite Pre-Market Dip

The investment reportedly marks AMD’s entry into life sciences, leveraging its AI chips for drug discovery.

Equity

The investment reportedly marks AMD’s entry into life sciences, leveraging its AI chips for drug discovery.


Absci Corp. is the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins. It partners with pharma and biotech innovators to create the next generation of protein-based drugs. The company was founded by Sean McClain in 2011 and is headquartered in Vancouver, WA.

Absci Corp

Will JP Morgan Chase ($JPM) beat quarterly earnings?  
 
*Powered by Polymarket

Stocktwits

JPMorgan Chase & Co

) beat quarterly earnings?  
 
*Powered by Polymarket

Current Price	$3.68
Prev Close	$3.76
Open	$3.81
Dividend Yield	0.00%
50-Day Moving Average	$2.76
Beta	2.19
Avg. Volume	4.74M
PE Ratio	-3.98

52-Week High	$6.33
52-Week Low	$2.01
Market Capitalization	$562.21M
EPS (Annual)	-$0.9353
Price to Book	2.77
Revenue Per Employee	$28,878.98
Enterprise Value/EBITDA	N/A

ABSI Absci Corp

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ABSI News